HIV‐associated Burkitt lymphoma in the combination antiretroviral therapy era: Real‐world outcomes and prognostication

Abstract

We performed a retrospectively study to analyze the clinical characteristics and outcomes of HIVassociated Burkitt's lymphoma in Chongqing University Cancer Hospital (CUCH), southwest China, from March 2012 to February 2022. In the entire cohort, the median age was 36 years (range, 28-60 years), and more patients were male (82.4%). The median CD4 + T cell count was 214/μl (range, 54-601), of whom 47.1% had a CD4 + T cell count below 200/μl. Most patients had elevated LDH, elevated β 2 -MG, extranodal involvement and advanced Ann Arbor stage at diagnosis. With a median follow-up of 11.5 months (range, 1.6-94.9 months), the overall 1-year PFS and OS rates were 27.6% and 47.6% respectively.The 1-year OS times in the LDH<3 upper limit of normal and LDH≥3 upper limit of normal groups were 62.5% and 31.3%, respectively (p=0.008). The 1-year OS times in the received <4 cycles and ≥4 cycles groups were 0 and 77.8%, respectively (p<0.001). These results demonstrated that LDH<3 upper limit of normal and received ≥4 cycles chemotherapy were signi cantly associated with improved outcomes. However, rituximab administration was not signi cantly associated with improved outcomes.

Readmission rates in HIV-associated Burkitt lymphoma patients: A nationwide readmission database (NRD) analysis

“…Our ndings further support previous data indicating that outcomes among HIV-associated BL patients are no longer associated with HIV speci c features but are more likely to be associated with cancer and treatment speci c features. 7,8 Notably, our results showed between-HIV status disparities in socioeconomic factors, particularly income quartiles. Of HIV-associated BL patients, 38.2% were in the lowest income quartile compared to 23.6% of HIV-negative BL patients (p < 0.001).…”

“…5,6 Additionally, evidence shows that outcomes of HIV-associated Burkitt lymphoma are based on tumor and cancer speci c factors, as opposed to HIV speci c factors. 7,8 Current literature acknowledges worse outcomes in PLWH with comorbid BL, however, there is minimal research into the signi cance of these outcomes, particularly considering hospital admissions and readmissions. Further exploration on these factors can give clinicians a greater awareness of possible outcomes to better inform their treatment decisions for this population.…”

Outcome in patients with HIV-associated Hodgkin lymphoma treated with chemotherapy using Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine in the combination antiretroviral therapy (cART) era: results of a multicenter study from China

“…Since the 1990s, with the widespread use of cART, the life expectancy of HIV-infected individuals has signi cantly increased [9][10][11]. A large cohort study from Denmark followed 5,701 HIV-infected individuals and 28,505 matched healthy individuals and found that the median age at death increased from 34.5 years in 1995-1996 to 73.9 years in 2010-2015 [12].…”

Outcome in patients with HIV-associated Hodgkin lymphoma treated with chemotherapy using Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine in the combination antiretroviral therapy (cART) era: results of a multicenter study from China

“…Since the 1990s, with the widespread use of cART, the life expectancy of HIV-infected individuals has significantly increased [ 9 – 11 ]. A large cohort study from Denmark followed 5,701 HIV-infected individuals and 28,505 matched healthy individuals and found that the median age at death increased from 34.5 years in 1995–1996 to 73.9 years in 2010–2015 [ 12 ].…”